Positron emission tomography (PET) ligands binding to aggregates of the protein tau, the main pathological hallmark of Alzheimer’s disease (AD) alongside amyloid-β (Aβ), are powerful biomarkers that promise improved diagnostics, endpoints in treatment development studies and an improved understanding of AD pathophysiology [1]. This evidence concerns the gene MAPT and Alzheimer disease.